Candel Therapeutics names Mark Sims chief commercial officer

Candel Therapeutics, Inc.

Candel Therapeutics, Inc.

CADL

0.00
  • Candel named Mark Sims chief commercial officer, effective July 6, 2026, to lead launch readiness for aglatimagene besadenovec in localized prostate cancer.
  • Move supports a planned Biologics License Application submission in Q4 2026, targeting a potential 2027 launch.
  • Sims most recently was VP and global franchise head for EGFRm lung cancer at AstraZeneca, leading global commercial strategy for a major franchise.
  • He previously held senior oncology roles at AstraZeneca, spent about a decade at Novartis, earlier worked at Idenix Pharmaceuticals, Merck.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Candel Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606250805PRIMZONEFULLFEED9752058) on June 25, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.